Back to search results

Evaluating Molecular Tumor Board Recommendations for Cancer Treatment

This study, called CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth, is looking at how recommendations from a team of experts, called a Molecular Tumor Board (MTB), affect treatment decisions for people with cancer. The MTB looks at your tumor's genetic profile (a detailed look at its genes) to suggest treatments like tumor-targeted drugs or immunotherapy. To join, your tumor must have specific genetic changes, and your genetic profiling must include at least 100 genes. The study will track whether your doctor uses the MTB's recommendations at 3 and 12 months after they are made. This study aims to enroll 192 adults.

Study design
This is a single-arm study, meaning all participants receive the same intervention, which is evaluation by the Molecular Tumor Board. It aims to enroll 192 participants.
What's involved
You will provide verbal informed consent. Your tumor genetic profiling, done as standard care, will be reviewed by the Molecular Tumor Board.
Compensation
Not stated in the trial record.
Follow-up
The study measures the impact of recommendations at 3 months and 12 months after they are made.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05405413

CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth

Recruiting
PHASE2Ages 18+InterventionalTreatment
Dartmouth-Hitchcock Medical Center
~192 participants
Updated 2025-10-20 on ClinicalTrials.gov
What's tested:Treatment recommendations made by Molecular Tumor Board.

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of subjects for whom evaluation by Molecular Tumor Board impacts treatment decisions as reported by the treating physician.
Measured over 3 months after recommendation
+1 more outcome measured

Conditions

Cancer

Explore related trials

Malignant Neoplasm

Where it's being run

1 sites across 1 states
New Hampshire1

Who to contact

Laura J Tafe, MD
[email protected]
(603) 650-7211
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Subject must provide verbal informed consent for study participation prior to MTB case evaluation.
Tumor genetic profiling performed as standard of care must include ≥100 genes.
Tumor must contain at least one of the following genetic alterations: (A) an alteration known to be potentially associated with sensitization to a clinically available treatment. (the list of genetic alterations evolves as new information emerges and new drugs are developed); (B) an alteration suspected to be germline.
Subject must have ECOG Performance Status of 0 to 2.
Subject must have measurable or evaluable disease.
Subjects who have previously enrolled in this study can be enrolled a second time if they undergo genetic profiling of a tumor that was biopsied/sampled AFTER progression on an intervening line of treatment started after the time of first enrollment. Re-enrollment of such subjects must be noted in REDCap to facilitate longitudinal analysis.
Age ≥18 years.

Exclusion

Subjects with a tumor harboring a genetic alteration for which an FDA-approved drug is indicated that the patient has not yet received (example for exclusion: a melanoma with a BRAF-V600E mutation in a subject who has not yet been treated with a BRAF inhibitor).
Pregnant women.

What this trial measures

  • Proportion of subjects for whom evaluation by Molecular Tumor Board impacts treatment decisions as reported by the treating physician.3 months after recommendation

    Treating physicians will complete surveys at 3 months after Molecular Tumor Board recommendations are made. Survey response from the treating physician indicating how Molecular Tumor Board recommendations impacted treatment decisions.

  • Proportion of subjects for whom evaluation by Molecular Tumor Board impacts treatment decisions as reported by the treating physician.12 months after recommendation

    Treating physicians will complete surveys at 12 months after Molecular Tumor Board recommendations are made. Survey response from the treating physician indicating how Molecular Tumor Board recommendations impacted treatment decisions.